Business Description
Arrowhead Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US04280A1007
Total Employee Number:
711Description
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.8 | |||||
Equity-to-Asset | 0.27 | |||||
Debt-to-Equity | 1.61 | |||||
Debt-to-EBITDA | -7.36 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 4.04 | |||||
Beneish M-Score | 1.16 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 39 | |||||
3-Year EPS without NRI Growth Rate | 81.8 | |||||
3-Year Book Growth Rate | -3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -465.71 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 72.54 | |||||
9-Day RSI | 67.78 | |||||
14-Day RSI | 64.27 | |||||
3-1 Month Momentum % | 19.08 | |||||
6-1 Month Momentum % | 9.24 | |||||
12-1 Month Momentum % | 341.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.23 | |||||
Quick Ratio | 6.23 | |||||
Cash Ratio | 6.04 | |||||
Days Sales Outstanding | 29.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.6 | |||||
Shareholder Yield % | -1.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -35.67 | |||||
Net Margin % | -48.38 | |||||
EBITDA Margin % | -21.62 | |||||
FCF Margin % | -8.39 | |||||
OCF Margin % | -6.04 | |||||
ROE % | -52.72 | |||||
ROA % | -18.32 | |||||
ROIC % | -40.26 | |||||
3-Year ROIIC % | 179.26 | |||||
ROC (Joel Greenblatt) % | -37.69 | |||||
ROCE % | -11.48 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 399.19 | |||||
PS Ratio | 18.85 | |||||
PB Ratio | 19.23 | |||||
Price-to-Tangible-Book | 19.39 | |||||
EV-to-EBIT | -68.94 | |||||
EV-to-Forward-EBIT | 440.67 | |||||
EV-to-EBITDA | -81.95 | |||||
EV-to-Forward-EBITDA | -23.32 | |||||
EV-to-Revenue | 17.72 | |||||
EV-to-Forward-Revenue | 25 | |||||
EV-to-FCF | -216.61 | |||||
Price-to-GF-Value | 1.62 | |||||
Price-to-Median-PS-Value | 0.66 | |||||
| Price-to-Net-Current-Asset-Value | 63.74 | |||||
| Price-to-Net-Cash | 91.63 | |||||
Earnings Yield (Greenblatt) % | -1.45 | |||||
FCF Yield % | -0.43 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Arrowhead Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 531.855 | ||
| EPS (TTM) (€) | -1.861 | ||
| Beta | 1.1174 | ||
| 3-Year Sharpe Ratio | 0.66 | ||
| 3-Year Sortino Ratio | 1.24 | ||
| Volatility % | 63.12 | ||
| 14-Day RSI | 64.27 | ||
| 14-Day ATR (€) | 2.173411 | ||
| 20-Day SMA (€) | 68.436 | ||
| 12-1 Month Momentum % | 341.87 | ||
| 52-Week Range (€) | 12.495 - 73.3 | ||
| Shares Outstanding (Mil) | 140.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Arrowhead Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Arrowhead Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2026-11-25 16:30 | In 143 days | ||
| Annual report for 2026 | 2026-11-25 | In 142 days | ||
| Fourth quarter earnings results for 2026 | 2026-11-25 | In 142 days | ||
| Third quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 33 days | ||
| Third quarter earnings results for 2026 | 2026-08-07 | In 32 days | ||
| Guidance call for 2026 | 2026-06-29 11:30 | 68.20 (-1.13%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 09:00 | 63.34 (-0.35%) | ||
| Guidance call for 2026 | 2026-05-20 09:00 | 62.92 (-0.06%) | ||
| Guidance call for 2026 | 2026-05-13 10:00 | 66.32 (+1.16%) | ||
| Second quarter earnings conference call for 2026 | 2026-05-07 16:30 | 67.36 (+6.05%) |
Show
Entries
Arrowhead Pharmaceuticals Inc Frequently Asked Questions
What is Arrowhead Pharmaceuticals Inc(FRA:HDP1)'s stock price today?
The current price of FRA:HDP1 is €73.30. The 52 week high of FRA:HDP1 is €73.30 and 52 week low is €12.50.
When is next earnings date of Arrowhead Pharmaceuticals Inc(FRA:HDP1)?
The next earnings date of Arrowhead Pharmaceuticals Inc(FRA:HDP1) is 2026-08-07 Est..
Does Arrowhead Pharmaceuticals Inc(FRA:HDP1) pay dividends? If so, how much?
Arrowhead Pharmaceuticals Inc(FRA:HDP1) does not pay dividend.
Press Release
Articles on Arrowhead Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers